A Study of Lasmiditan (LY573144) Over Four Migraine Attacks

NCT03670810 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1633

Enrollment

INDUSTRY

Sponsor class

Conditions

Migraine

Interventions

DRUG: Lasmiditan
DRUG: Placebo

Sponsor

Eli Lilly and Company